Key result
Real-time perfusion echocardiography demonstrated that cardiac tumors have greater microvascular blood volume than thrombi, and an A value >3.28 dB at peak dipyridamole stress conferred a 5.8-times higher chance of a mass being a malignant rather than benign tumor.
Why the study?
Does real-time perfusion echocardiography improve the diagnostic differentiation of cardiac masses in patients with suspected tumors or thrombi?
Observational (n=86)
Single-blind
No
Does real-time perfusion echocardiography improve the diagnostic differentiation of cardiac masses in patients with suspected tumors or thrombi?
Odds Ratio: 5.8
Real-time perfusion echocardiography, particularly with quantitative analysis and dipyridamole stress, is a highly accurate method for differentiating cardiac tumors from thrombi and malignant from benign tumors.
May aid noninvasive differentiation of cardiac masses; leaves open prospective validation before clinical adoption.
BACKGROUND: Diagnosis of cardiac masses is still challenging by echocardiography and distinguishing tumors from thrombi has important therapeutical implications. We sought to determine the diagnostic value of real-time perfusion echocardiography (RTPE) for cardiac masses characterization. METHODS: We prospectively studied 86 patients, 23 with malignant tumors (MT), 26 with benign tumors (BT), 33 with thrombi and 6 with pseudotumors who underwent RTPE. Mass perfusion was analyzed qualitatively and blood flow volume (A), blood flow velocity (β), and microvascular blood flow (A x β) were determined by quantitative RTPE. RESULTS: Logistic regression models showed that the probability of having a tumor increased by 15.8 times with a peripheral qualitative perfusion pattern, and 34.5 times with a central perfusion pattern, in comparison with the absence of perfusion. Using quantitative RTPE analysis, thrombi group had parameters of blood flow lower than tumor group. A values for thrombi, MT, and BT were 0.1 dB (0.01-0.22), 2.78 dB (1-7) and 2.58 dB (1.44-5), respectively; p < 0.05, while A x β values were 0.0 dB/s(-1) (0.01-0.14), 2.00 dB/s(-1) (1-6), and 1.18 dB/s(-1) (0.52-3), respectively; p < 0.05. At peak dipyridamole stress, MT had greater microvascular blood volume than BT [A = 4.18 dB (2.14-7.93) versus A = 2.04 dB (1.09-3.55); p < 0.05], but no difference in blood flow [Axβ = 2.46 dB/s(-1) (1.42-4.59) versus Axβ = 1.55 dB/s [1] (0.51-4.08); p = NS]. An A value >3.28 dB at peak dipyridamole stress predicted MT (AUC = 0.75) and conferred 5.8-times higher chance of being MT rather than BT. CONCLUSION: RTPE demonstrated that cardiac tumors have greater microvascular blood volume and regional blood flow when compared with thrombi. Dipyridamole stress was useful in differentiating MT from BT.
No takes yet. Share an insight, caveat, or question.
Uenishi et al. (2015) conducted an observational in Cardiac masses (n=86). Real-time perfusion echocardiography (RTPE) vs. Thrombi vs Tumors / Benign vs Malignant Tumors was evaluated on Prediction of malignant tumor using microvascular blood volume (A) > 3.28 dB at peak dipyridamole stress (OR 5.8). Real-time perfusion echocardiography demonstrated that cardiac tumors have greater microvascular blood volume than thrombi, and an A value >3.28 dB at peak dipyridamole stress conferred a 5.8-times higher chance of a mass being a malignant rather than benign tumor.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: